TrialJournal of clinical pharmacology2020

Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.

Robert Provenzano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.